Regeneron Pharmaceuticals, Inc. REGN
951.19 USD -8.22 (-0.86%)
At closeNov 13, 2026, 7:13 AM EST
946.98 -4.22 -0.44%
Pre-market · Nov 13, 7:13 AM ET
944.71 Day range 981.55
591.52 52-week range 991.73
- YTD
- +23.23%
- 1 year
- +36.86%
News
globenewswire.com POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms Data presented today for the first time at the American Autonomic Society (AAS) annual meeting POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked…
benzinga.com If You Invested $1000 In Regeneron Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 8.79% on an annualized basis producing an average annual return of 21.73%. Currently, Regeneron…
zacks.com REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock? Regeneron's strong Eylea HD and Dupixent sales, expanding oncology portfolio and promising pipeline fuel growth prospects as Eylea faces intensifying competition.
zacks.com Why Regeneron (REGN) is a Top Value Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
fool.com Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT? One fund holds about 60 drug companies at a lower fee. The other holds 30 biotech names and has a stronger long-term record. Either way, expect some volatility.
benzinga.com Brightview Posts Downbeat Q4 Results, Joins Astronics, Spire Global And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. futures rose, but BrightView plunged 17.7% after missing earnings and sales estimates; Lightwave Logic and others also fell premarket.
seekingalpha.com Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH Transcript Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH Transcript
247wallst.com Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later? One biotech pays retirees a bigger check today, while the other carries no net debt and is growing far faster. We put Amgen and Regeneron side by side on income, valuation, and growth to see which…
marketbeat.com Regeneron Pharmaceuticals Advances Liver Drug After Early Trial Cuts Liver Fat by Up to 80% Regeneron Pharmaceuticals NASDAQ: REGN is advancing its experimental CIDEB therapy into later-stage studies for a form of liver disease after an early trial showed a single dose substantially reduced…
benzinga.com Alnylam And Regeneron Says Data Published In The The New England Journal Of Medicine, Reports Up To 80% Reduction In Liver Fat Sustained For 36 Weeks After Single CIDEBsiRNA Dose In MASLD Patients Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeksData shared in oral presentation at AASLD The Liver…
247wallst.com 3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one with the smallest yield may be hiding the sturdiest payout of all.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
fool.com The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation These are among the best the industry has to offer.
globenewswire.com CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD Single administration of CIDEB siRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks
defenseworld.net Regeneron Pharmaceuticals (NASDAQ:REGN) Stock: Insider Huda Zoghbi Sells 7,439 Shares Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) Director Huda Zoghbi sold 7,439 shares of the firm's stock in a transaction on Tuesday, November 3rd. The stock was sold at an average…
defenseworld.net Regeneron Pharmaceuticals (NASDAQ:REGN) EVP Sells $4,311,878.34 in Stock Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) EVP Joseph Larosa sold 4,466 shares of the firm's stock in a transaction dated Monday, November 2nd. The stock was sold at an average…
benzinga.com Drugmaker CEOs Say AI Alone Can't Cure Diseases, Challenge Silicon Valley's Bold Predictions: 'To Say AI Is Going to Cure Cancer...' Drugmaker executives doubt AI will cure disease soon, saying biology is too complicated.
benzinga.com UnitedHealth, Cleveland-Cliffs, Regeneron Pharmaceuticals And More: CNBC’s ‘Final Trades’ CNBC traders picked RSP, Cleveland-Cliffs, UnitedHealth and Regeneron; REGN surged after strong Q3 earnings, while RSP also gained.- benzinga.com Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997 Leerink Partners analyst David Risinger maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $835 to $997.
benzinga.com Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812 Bernstein analyst Jeffrey Walch maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Market Perform and raises the price target from $756 to $812.
benzinga.com Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855 Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $779 to $855.
benzinga.com RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913 RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $810 to $913.
benzinga.com Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982 Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $780 to $982.- benzinga.com Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1100 Guggenheim analyst Yatin Suneja maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1030 to $1100.
benzinga.com These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results Regeneron beat Q3 estimates with EPS up 70% and revenue up 36%; analysts raised price targets to as high as $1,175.
benzinga.com Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $925 Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $750 to $925.
benzinga.com Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter Regeneron, AstraZeneca and Exelixis show overbought RSI readings after strong gains, warning momentum-focused investors of potential pullbacks.
benzinga.com Evercore ISI Group Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1075 Evercore ISI Group analyst Cory Kasimov maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $900 to $1075.
benzinga.com Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.
benzinga.com Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1175 Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $922 to $1175.- benzinga.com Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $980 Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $795 to $980.
benzinga.com Baird Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $875 Baird analyst Brian Skorney maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $761 to $875.- benzinga.com B of A Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030 B of A Securities analyst Tazeen Ahmad maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $908 to $1030.
benzinga.com Alphabet Posts Worst Week Since 2011, Intel Suffers Record Crash as Warsh Sees 'Cracks': This Week on Wall Street Alphabet logs its worst week since 2011 and Intel its worst day ever as the AI trade cracks, while health care posts a record month against the market.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.…
benzinga.com Nasdaq Tumbles Over 3%, Chip Stocks Sink: Stock Market Today Intel nears its worst day on record after weak guidance, sinking chip stocks as SMH falls 7.0% and the Nasdaq 100 drops 3.2%.
benzinga.com Regeneron Eyes One of Its Strongest Years Ever, Stock Jumps Regeneron stock hits a 52-week high as earnings surge 70%, revenue jumps 36% and key drugs deliver record sales.
benzinga.com AutoNation, Regeneron Pharmaceuticals, AstraZeneca And Other Big Stocks Moving Higher On Friday U.S. stocks fell Friday, but AutoNation jumped 8% after beating Q3 estimates; OneSpan, Grid Dynamics and others posted double-digit gains.
benzinga.com Regeneron Pharmaceuticals Q3 2026 Earnings Call Transcript Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…- benzinga.com Regeneron Pharmaceuticals Q3 Adj. EPS $20.07 Beats $16.19 Estimate, Sales $5.116B Beat $4.542B Estimate Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $20.07 per share which beat the analyst consensus estimate of $16.19 by 23.97 percent. This is a 69.65 percent increase over…
benzinga.com Top Wall Street Forecasters Revamp Regeneron Pharmaceuticals Expectations Ahead Of Q3 Earnings Regeneron expects Q3 EPS of $16.19 and revenue of $4.56B; extended BARDA’s Inmazeb supply deal as analysts raise price targets.
benzinga.com ExxonMobil, AbbVie On Deck Friday As Energy, Drug Growth Face Test ExxonMobil headlines Friday’s reports, with investors watching whether strong energy production can sustain a sharp earnings recovery. AbbVie, Chevron, AstraZeneca, BP, Sanofi, General Dynamics,…- benzinga.com Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $922 Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $875 to $922.
benzinga.com Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.58% on an annualized basis producing an average annual return of 19.53%. Currently, Regeneron…
benzinga.com Regeneron Pharma Extends Agreement With BARDA, Part Of ASPR Within US Department Of HHS, To Provide Additional Supply Of Inmazeb For US Preparedness Against Ebola Disease Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 millionTARRYTOWN,…- benzinga.com TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $980 TD Cowen analyst Tyler Van Buren maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $960 to $980.
- benzinga.com Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865 Piper Sandler analyst Biren Amin maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $854 to $865.
- benzinga.com Regeneron Pharma Says EMA’s CHMP Adopts Positive Opinion Recommending Approval Of Alternative Dosing Schedule For Libtayo Across All Approved Indications Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatmentOptional reduction of infusion time for 350 mg dose to 15 to 30…
- benzinga.com UBS Upgrades Regeneron Pharmaceuticals to Buy, Raises Price Target to $978 UBS analyst Trung Huynh upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Neutral to Buy and raises the price target from $660 to $978.
benzinga.com Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth Regeneron's Pasatru shows sustained efficacy in halting new bone growth and reducing flare-ups in adults with FOP in an 84-week trial.